William F Doyle
CIK 1194459 · Executive Chairman · last filed 2026-05-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NVCR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
PORTSMOUTH, NH 08301
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PROK | Director | — | $1.48 | — | $0 | 4 | 2026-05-29 |
| NVCR | Executive Chairman | 766,564 | $15.57 | $11.94M | -$73.23M | 39 | 2026-03-05 |
| ELAN | Director | 94,499 | $22.80 | $2.16M | $499.2K | 4 | 2024-12-03 |
| Elanco Animal Health Inc (ELAT) Delisted | Director | 25,956 | $21.32 | $553.4K | $0 | 2 | 2022-12-02 |
| NERV | Director | 3,264 | $2.50 | $8.2K | $223.0K | 16 | 2022-06-28 |
| OptiNose, Inc. (OPTN) Delisted | Director | 55,736 | $9.60 | $535.1K | $0 | 5 | 2020-06-12 |
| ZTS | 0 | $79.92 | $0 | $0 | 1 | 2016-05-12 |
Recent Filings · Page 6 of 8
73 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-10-15 | NERV | Buy (P) | +600 | $6.0K | EDGAR |
| 2018-09-19 | NERV | Buy (P) | +1,800 | $18.9K | EDGAR |
| 2018-09-17 | NERV | Buy (P) | +2,200 | $23.1K | EDGAR |
| 2018-09-11 | NERV | Buy (P) | +8,011 | $78.5K | EDGAR |
| 2018-08-20 | NVCR | Other (J) | −187,787 | $0 | EDGAR |
| 2018-08-02 | NERV | Grant (A) | — | $0 | EDGAR |
| 2018-07-18 | NVCR | Exer (M) | +2,330 | $8.4K | EDGAR |
| 2018-07-02 | OptiNose, Inc. (OPTN) Delisted | Other (J) | −2,195,914 | $0 | EDGAR |
| 2018-06-11 | OptiNose, Inc. (OPTN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-11 | NERV | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.